Myopia Progression and the Effect of 7-Methylxanthine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00263471
Recruitment Status : Unknown
Verified October 2003 by Trier Research Laboratories. Recruitment status was: Active, not recruiting
First Posted : December 8, 2005
Last Update Posted : December 14, 2005
Trier Research Laboratories
Generalkonsul Einar Høyvalds Fond
Jørgen Bagenkop Nielsens Myopi-Fond
Chr. Andersen og hustru Ingeborg Andersen, f. Schmidts legat (fond) oprettet af deres datter, frk. Lilli Ellen Andersen.
7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.
Condition or disease
Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. The participants are interviewed about possible CNS, gastrointestinal, or cardiopulmonal side effects.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
8 Years to 13 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.
Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)